"epidermal glands called elaiophores" trang 10 - tải miễn phí từ tailieuXANH
Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer

Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer
11    136    0
A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)
7    103    0
Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations

Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations
7    97    0
Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: A systematic review and meta-analysis

Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: A systematic review and meta-analysis
7    73    0
Erlotinib treatment after platinum-based therapy in elderly patients with non-smallcell lung cancer in routine clinical practice – results from the ElderTac study

Erlotinib treatment after platinum-based therapy in elderly patients with non-smallcell lung cancer in routine clinical practice – results from the ElderTac study
11    60    0
Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive /HER2-negative breast cancer

Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive /HER2-negative breast cancer
9    64    0
Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
7    50    0
Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): An open-label, non-randomized, multicenter, phase IV clinical trial

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): An open-label, non-randomized, multicenter, phase IV clinical trial
7    74    0
EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence

EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence
10    49    0
Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma

Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma
9    53    0
Cetuximab for esophageal cancer: An updated meta-analysis of randomized controlled trials

Cetuximab for esophageal cancer: An updated meta-analysis of randomized controlled trials
13    106    0
Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
7    55    0
Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study

Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study
13    77    0
Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: A case report

Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: A case report
6    55    0
Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: Study protocol for a randomized controlled trial

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: Study protocol for a randomized controlled trial
7    69    0
Case report: Primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation

Case report: Primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
4    73    0
Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
13    59    0
Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer

Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer
17    61    0
Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel

Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel
7    52    0
Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: Exploratory study using primary and paired metastatic lesions

Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: Exploratory study using primary and paired metastatic lesions
14    55    0
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.